Skip to main content

Table 2 Overview of patient characteristics

From: Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis

Trial

(reference)

Treatment arm

RF status

(% positive)

Gender (% F)

Mean age (years)

Mean years since diagnosis

Mean n of prior DMARDs

% pts on NSAIDs

% pts on corticoid steriods

Mean TJC

Mean SJC

Mean pts pain1 (100-mm VAS)

Mean pts GA 2 (100-mm VAS)

Mean phs GA3 (100-mm VAS)

Mean HAQ-DI

Mean CRP (mg/l)

Mean ESR (mm/h)

Abatacept studies

AIM [14, 18]

PBO + MTX;

ABA 10 mg/kg every four weeks + MTX

81.8

77.8

51.5

8.5

1.3

85.5

72.1

31.0

21.4

63.3

62.7

68.0

1.70

33

nr

  

78.5

81.7

50.4

8.9

1.2

82.6

68.5

32.3

22.1

65.9

62.8

67.4

1.70

28

 

Kremer et al. 2005, Kremer et al. 2003 [16, 17]

PBO + MTX

90.0

66.0

54.7

8.9

21%

nr

67.2

29.2

21.8

65.2

62.8

63.3

1.00

32

nr

 

ABA 2 mg/kg every four weeks + MTX

90.0

63.0

54.4

9.7

18.1%

 

67.6

28.2

20.2

64.5

59.4

61.0

1.00

32

 
 

ABA 10 mg/kg every four weeks + MTX

99.0

75.0

55.8

9.7

16.5%

 

60.0

30.8

21.3

62.1

60.1

62.1

1.00

29

 

ATTEST [15]

ABA 10 mg/kg every four weeks + MTX

87.2

83.3

49.0

7.9

1.7

85.3

75.6

31.6

21.3

nr

nr

nr

1.80

31

49.4

 

PBO + MTX

77.3

87.3

49.4

8.4

1.8

84.5

70.0

30.3

20.1

   

1.80

27

47.0

 

INF 3 mg/kg every eight weeks +MTX

84.8

82.4

49.1

7.3

1.7

86.1

71.5

31.7

20.3

   

1.70

33

47.8

Adalimumab studies

ARMADA [25]

PBO + MTX

mean IU/liter +- SD reported

82.3

56.0

11.1

3.0

nr

nr

28.7

16.9

57.2

58.0

58.9

1.64

31

nr

 

ADA 20 mg every other week + MTX

 

75.4

53.5

13.1

3.0

  

28.5

17.6

55.1

57.6

60.5

1.52

28

 
 

Adalimumab 40 mg every other week + MTX

 

74.6

57.2

12.2

2.9

  

28.0

17.3

53.0

56.9

58.7

1.55

21

 
 

ADA 80 mg every other week + MTX

 

75.3

55.5

12.8

3.1

  

30.3

17.0

55.0

58.8

62.6

1.55

28

 

DE019 [24]

ADA 40 mg every other week + MTX

81.6

76.3

56.1

11.0

2.4

nr

nr

27.3

19.3

55.9

52.7

62.0

1.45

18

nr

 

ADA 20 mg weekly + MTX

81.2

75.5

57.3

11.0

2.4

  

27.9

19.6

55.2

51.9

61.6

1.44

14

 
 

PBO + MTX

89.5

73.0

56.1

10.9

2.4

  

28.1

19.0

56.3

54.3

61.3

1.48

18

 

Certolizumab Pegol studies

RAPID I [26, 27, 29]

PBO + MTX

82.8

83.9

52.2

6.2

1.4

nr

nr

29.8

21.2

nr

nr

nr

1.70

16

45.0

 

CZP 200 mg every other week + MTX

79.6

82.4

51.4

6.1

1.3

  

30.8

21.7

   

1.70

16

43.5

 

CZP 400 mg every other week + MTX

83.6

83.6

52.4

6.2

1.3

  

31.1

21.5

   

1.70

14

42.5

RAPID II [28, 29]

PBO + MTX

78.2

84.3

51.5

5.6

1.2

nr

nr

30.4

21.9

59.9

59.9

65.7

1.60

14

40.8

 

CZP 200 mg every other week + MTX

77.5

83.7

52.2

6.1

1.2

  

30.1

20.5

61.8

62.4

64.3

1.60

14

43.7

 

CZP 400 mg every other week + MTX

75.5

78.0

51.9

6.5

1.3

  

30.0

21.0

60.5

61.1

62.8

1.60

13

39.1

Etanercept studies

Weinblatt et al. 1999 [32]

PBO + MTX

90.0

73.0

53.0

13.0

2.8

80.0

70.0

28.0

17.0

56.0

60.0

65.0

1.50

26

36.0

 

ETN 25 mg twice weekly + MTX

84.0

90.0

48.0

13.0

2.7

75.0

53.0

28.0

20.0

50.0

60.0

60.0

1.50

22

25.0

TEMPO [30, 31]

PBO + MTX

71.0

79.0

53.0

6.8

2.3

86.0

64.0

33.1

22.6

nr

nr

nr

nr

26

nr

 

ETN 25 mg twice weekly

75.0

77.0

53.2

6.3

2.3

88.0

57.0

35.0

23.0

    

32

 
 

ETN 25 mg twice weekly + MTX

76.0

74.0

52.5

6.8

2.3

88.0

62.0

34.2

22.1

    

30

 

Golimumab studies

GO-FORWARD [33, 34]

PBO + MTX

81.2

82.0

52.0

6.5

70.74

nr

nr

21.0

12.0

57.0

53.0

56.5

1.25

8

nr

 

GOL 100 mg every 4 weeks

83.5

78.9

51.0

5.9

75.9

  

22.0

11.0

60.0

56.0

58.0

1.38

9

 
 

GOL 50 mg every 4 weeks + MTX

86.5

80.9

52.0

4.5

78.7

  

26.0

13.0

61.0

60.0

61.0

1.38

10

 
 

GOL 100 mg every four weeks + MTX

84.3

80.9

50.0

6.7

75.3

  

23.0

12.0

64.0

59.0

61.0

1.38

9

 

Infliximab studies

ATTRACT [35, 36]

PBO + MTX

77.0

80.0

51.0

8.9

2.5

72.0

64.0

24.0

19.0

67.0

62.0

65.0

1.80

30

nr

 

INF 3 mg/kg every eight weeks +MTX

84.0

81.0

56.0

8.4

2.8

79.0

63.0

32.0

19.0

70.0

66.0

61.0

1.80

31

 
 

INF 3 mg/kg every four weeks +MTX

80.0

77.0

51.0

7.2

2.6

76.0

53.0

31.0

20.0

69.0

57.0

62.0

1.80

20

 
 

INF 10 mg/kg every eight weeks +MTX

82.0

77.0

55.0

9.0

2.5

77.0

57.0

30.0

20.0

67.0

64.0

64.0

1.80

25

 
 

INF 10 mg/kg every four weeks +MTX

82.0

73.0

52.0

8.7

2.5

68.0

65.0

35.0

23.0

66.0

60.0

60.0

1.50

24

 

Rituximab studies

DANCER [39, 40]

PBO + MTX

100

(efficacy analyses)

80.0

51.1

9.3

2.2

nr

nr

35.0

21.0

nr

nr

nr

1.70

33

40.0

 

RTX 500 mg * two injections + MTX

100

83.0

51.4

11.1

2.5

  

33.0

22.0

   

1.80

32

45.0

 

RTX 1,000 mg * two injections + MTX

100

80.0

51.1

10.8

2.5

  

32.0

22.0

   

1.70

30

41.0

Edwards et al. 2004 [41]

PBO + MTX

100

80.0

54.0

11.0

2.6

nr

nr

32.0

19.0

nr

nr

nr

nr

32

52.0

 

RTX 1,000 mg * two injections

100

73.0

54.0

9.0

2.5

  

34.0

21.0

    

26

47.0

 

RTX 1,000 mg * two injections +cyclophosphamide

100

83.0

53.0

10.0

2.6

  

33.0

19.0

    

40

55.0

 

RTX 1,000 mg * two injections + MTX

100

75.0

54.0

12.0

2.5

  

32.0

23.0

    

29

53.0

Tocilizumab studies

OPTION [43, 44]

PBO + MTX

78.0

78.0

50.6

7.8

1.7

68.0

nr

32.8

20.7

57.3

63.6

63.7

1.50

24

49.7

 

TCZ 4 mg/kg every four weeks + MTX

83.0

82.0

51.4

7.4

1.5

68.0

 

33.2

20.0

60.7

65.6

63.6

1.60

28

49.2

 

TCZ 8 mg/kg every four weeks + MTX

71.0

85.0

50.8

7.5

1.5

66.0

 

31.9

19.5

59.9

64.8

64.0

1.60

26

51.2

LITHE [42]

PBO + MTX

nr

nr

nr

nr

nr

nr

nr

nr

nr

nr

nr

nr

1.5

nr

nr

 

TCZ 4 mg/kg every four weeks + MTX

            

1.5

  
 

TCZ 8 mg/kg every four weeks + MTX

            

1.5

  
  1. The treatment arms in grey were not used in the network meta-analysis but are included as part of the trials.
  2. 1Patients assessment of pain (Pts Pain); 2Patients global assessment of disease activity (Pts GA); 3Physician global assessment of disease activity (Phs GA); 4% Patients with previous use of DMARD other than MTX. ABA, abatacept; ADA, adalimumab; CRP, C-reactive protein; CZP, certolizumab pegol; DMARD, Disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; ETN, etanercept; GA, global assessment; GOL, golimumab; HAQ, health assessment questionnaire; INF, infliximab; MTX, methotrexate; nr, not recorded; NSAID, non-steroidal anti-inflammatory drug; PBO, placebo; Pts, patients; RF, rheumatoid factor; RTX, rituximab; SJC, swollen joint count; TCZ, tocilizumab; TJC, tender joint count;
  3. No data for patient characteristics were available for the SERENE study.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us